Design Therapeutics (DSGN) Other Working Capital Changes (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Other Working Capital Changes of $300000.0 for Q1 2020.
Analysis
Design Therapeutics (DSGN) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Other Working Capital Changes for 7 years, with the latest figure at $391000.0 in Q2 2026.
- Other Working Capital Changes for Q2 2026 came in at $391000.0, up 186.5% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.1 million (up 454.52% YoY), and the FY2025 annual result was $1.4 million, up 708.85% from the prior year.
- Other Working Capital Changes held at $300000.0 in Q1 2020.
- Over five years, Other Working Capital Changes peaked at $1.9 million in Q3 2022 and troughed at -$1.2 million in Q1 2023.
- A 5-year average of $180388.9 and a median of $339000.0 in 2026 frame the typical range for Other Working Capital Changes.
- The widest annual swing landed in 2022, when Other Working Capital Changes surged 508.15%; it then tumbled 274.73% in 2023.
- A 5-year view of Other Working Capital Changes shows it stood at $471000.0 in 2022, then tumbled by 274.73% to -$823000.0 in 2023, then advanced by 26.49% to -$605000.0 in 2024, then jumped by 245.45% to $880000.0 in 2025, then tumbled by 55.57% to $391000.0 in 2026.
- Per Business Quant data, the three most recent Other Working Capital Changes figures were $391000.0 in Q2 2026, $287000.0 in Q1 2026, and $880000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Design Therapeutics | 945.71 Mn | 738.31 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 391,000.00 |
| Jun 30, 2026 | 391,000.00 |
| Mar 31, 2026 | 287,000.00 |
| Mar 31, 2026 | 287,000.00 |
| Dec 31, 2025 | 880,000.00 |
| Dec 31, 2025 | 880,000.00 |
| Sep 30, 2025 | -459,000.00 |
| Sep 30, 2025 | -459,000.00 |
| Jun 30, 2025 | -452,000.00 |
| Jun 30, 2025 | -452,000.00 |
| Mar 31, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | -605,000.00 |
| Dec 31, 2024 | -605,000.00 |
| Sep 30, 2024 | -660,000.00 |
| Sep 30, 2024 | -660,000.00 |
| Jun 30, 2024 | 628,000.00 |
| Jun 30, 2024 | 628,000.00 |
| Mar 31, 2024 | 411,000.00 |
| Mar 31, 2024 | 411,000.00 |